SRNE, US83587F2020

Sorrento Therapeutics follows a liquidation plan: what it means for Sorrento Therapeutics stock

Published on 10/02/2026 at 03:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sorrento's Chapter 11 plan became liquidation on November 30, 2023. Sorrento Therapeutics stock is listed OTC with USD 0.4 million market value.

SRNE, US83587F2020, Illustration mit AI erstellt.

Sorrento Therapeutics (US83587F2020) follows a Chapter 11 liquidation plan approved on November 30, 2023, a status that continues to define the investment case. Investing.com identifies the security as SRNE on OTC Markets and describes the liquidation approval date.

Liquidation plan sets the frame

Sorrento filed its voluntary Chapter 11 petition on February 13, 2023, according to Investing.com. The plan received approval on November 30, 2023, changing the company context from an operating biotech story to a liquidation-linked security.

A June 29, 2026 legal update adds a current procedural marker: Law360 lists a Sorrento case item headed Sorrento Case Stopped, Spanish Broadcasting Plan OK'd. The court process therefore remains a central reference point for interpreting SRNE rather than conventional earnings growth.

Biotech profile has two segments

Sorrento's operating profile covers biotechnology research and commercial activities, with two segments named Sorrento Therapeutics and Scilex. The company profile lists 949 full-time employees and identifies cancer therapeutics, autoimmune disorders, inflammatory diseases, viral infections and neurodegenerative conditions among its target areas.

The investor-relations page records a September 22, 2023 announcement on the sale of substantially all Scilex shares, preferred shares and warrants held by Sorrento. It also records a September 12, 2023 update on a Phase 3 trial for Ovydso, an oral Mpro inhibitor, linking the historical pipeline to the corporate restructuring context.

Market value remains a key signal

SRNE's market capitalization stood at USD 0.4 million as of October 2, 2026. That figure places the security in a highly speculative micro-cap category, where legal outcomes and asset dispositions can matter more than standard revenue multiples.

For investors assessing Sorrento Therapeutics stock, the practical takeaway is the hierarchy of evidence: the November 30, 2023 liquidation approval, the February 13, 2023 Chapter 11 filing and the June 29, 2026 case update all precede any conventional analysis of pipeline value.